Forat Lutfi, MD
Hematology · Westwood, KSNPI 1902269335
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $9,600 of the $12,244 with a category attached, or 78.4%. ADC Therapeutics America, Inc. accounts for 90.4% of it on its own, with 11 other manufacturers making up the rest. Reporting peaked in 2024 at $10,889 and has fallen 92.1% since, to $855 in 2025.
Across 32 payments — averaging $382.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- ADC Therapeutics America, Inc.$11K
- AstraZeneca$224
- Bristol Myers Squibb$157
- Janssen Research & Development, LLC$146
- Genmab U.S., Inc.$143
- Adaptive Biotechnologies Corporation$131
- plus $372 from 6 others
What the payments were for
- Consulting fees$9,60078%
- Travel & lodging$7716%
- Food & beverage$1,87415%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| ADC Therapeutics America, Inc. | 15 | $11,071 |
| AstraZeneca | 2 | $224 |
| Bristol Myers Squibb | 3 | $157 |
| Janssen Research & Development, LLC | 1 | $146 |
| Genmab U.S., Inc. | 2 | $143 |
| Adaptive Biotechnologies Corporation | 1 | $131 |
| Johnson & Johnson | 1 | $122 |
| Astellas Pharma US Inc | 1 | $101 |
| AbbVie | 2 | $67 |
| Gilead | 2 | $45 |
| Merck | 1 | $19 |
| Genentech USA, Inc. | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
Too few hematology providers in Kansasto place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ShingrixVaricella-Zoster Ge/As01b/Pf | 23 | $4,236 |
| Menveo A-C-Y-W-135-DipMening Vac A,c,y,w-135 Dip/Pf | 23 | $3,439 |
| PentacelDipht,pert(A),tet-Polio/Hib/Pf | 29 | $3,058 |
| Acyclovir | 88 | $1,623 |
| Dapsone | 19 | $849 |
| Gabapentin | 29 | $543 |
| Duloxetine Hcl | 13 | $283 |
| Levofloxacin | 14 | $230 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 54 | $220 |
| Dexamethasone | 13 | $208 |
| Pantoprazole Sodium | 26 | $203 |
| Allopurinol | 21 | $71 |
| Prednisone | 15 | $67 |
| Klor-Con M20Potassium Chloride | 11 | $9 |
Paid to pharmacies, not to this prescriber.
Other hematology in Westwood
- Nausheen AhmedWestwood$61K
- Aung TunWestwood$17K
- Alma HabibWestwood$369
- Konstantine HalkidisKansas City$16K
- Barry SkikneKansas City$4K
- Robert KribsKansas City$824
- Edwin PetrikTopeka$779
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.